Tg(tetO-APPSwInd)102Dbo
Transgene Detail
|
Symbol: |
Tg(tetO-APPSwInd)102Dbo |
Name: |
transgene insertion 102, David R Borchelt |
MGI ID: |
MGI:3708167 |
Synonyms: |
tet-APPswe/ind (line 102), tet-APPswe/ind line 102, Tg(tetO-APP*Swe*Ind)102Dbo |
Transgene: |
Tg(tetO-APPSwInd)102Dbo Location: unknown
|
Alliance: |
Tg(tetO-APPSwInd)102Dbo page
|
|
|
Transgene Type: |
|
Transgenic (Humanized sequence, Inducible, Inserted expressed sequence) |
Inducer: |
|
doxycycline/tetracycline |
Mutation: |
|
Insertion
|
|
|
Tg(tetO-APPSwInd)102Dbo expresses
1 gene
Transgene expresses:
Organism |
Expressed Gene |
Note |
mouse |
App (MGI:88059) |
The gene encodes a humanized amyloid beta domain and incorporates the Swedish and Indiana mutations. |
|
|
|
Tg(tetO-APPSwInd)102Dbo expression driven by
1 gene
Transgene expression driven by:
Organism |
Driver Gene |
Note |
Not Specified |
tetO |
|
|
|
|
Mutation details: The mouse amyloid beta (A4) precursor protein (APP) sequence was modified to contain a humanized amyloid-beta (Abeta) domain. This mouse/human chimeric APP (mo/huAPP695 or APP695) was mutated to incorporate the Swedish (KM570/571NL) and Indiana (V617F) APP mutations associated with Alzheimer's disease. This APP695swe/ind sequence was placed downstream of the tetracycline-responsive (TRE or tetO) promoter and mouse prion protein exons 1-2. Line 102 was established. When mice are crossed with a line expressing a tTA transgene, these mice show the greatest doxycycline sensitivity for transgene suppression.
(J:80782, J:109829)
|
|
|
View phenotypes and curated references for all genotypes (concatenated display).
|
|
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 1 strain available
Cell Lines: 0 lines available
|
|
Original: |
J:109829 Jankowsky JL, et al., Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005 Dec;2(12):e355 |
All: |
24 reference(s) |
|